Monday, August 31, 2009

The Medicinal Life of Bees


Forms of apitherapy or bee venom therapy (BVT) have been in use for centuries in a number of cultures worldwide. As early as 800 BCE Charlemagne is said to have been treated with bee stings, and in 1888 Australian physician advocated the use of bee venom for rheumatism. Apitherapy is defined as the medicinal use of products derived from bees, including honey and royal jelly, as well as bee venom. While BVT has not been proven through clinical trials and testing, practitioners claim that bee stings contain an anti-inflammatory agent that relieves chronic pain and can be used to treat a number of diseases. BVT, which can involve either the application of live bees or the injection of bee venom, has been used to treat arthritis, multiple sclerosis, migraine headaches, psoriasis, and herpes. Raw honey and other ingested bee products are believed by some to contain B-complex vitamins, antifungal, and antibacterial properties.

The use of BVT has gained some attention as a potential homeopathic remedy for the treatment of multiple sclerosis (MS) symptoms. Discovery Health reports that apitherapy can be used to lessen the pain, loss of coordination, and muscle weakness associated with MS. It is commonly held that compounds in bee venom, including melittin and adolapin, help to reduce inflammation and pain. Because of the lack of major studies to date regarding the effectiveness of BVT, only about 50 physicians in the United States use it as a treatment for MS and other diseases. Anecdotal evidence from patients with MS being treated with apitherapy is reassuring, however, and has prompted thousands of beekeepers, acupuncturists, and other alternative medicine providers to offer the treatment. Those who chose to use apitherapy methods based on the application of live bees may chose to raise their own colonies or rely on mail-order services.

Researchers at Georgetown University (Washington, D.C.) conducted a preliminary study to evaluate the safety of bee venom extract as a treatment for patients with progressive forms of MS. Although no serious adverse reactions were observed during the year-long study, four of the nine participants experienced a worsening of neurological symptoms, requiring termination of the study. It is important to note that this worsening could not be ascribed to side effects of the study, and three participants self-reported an improvement in their symptoms, and two demonstrated objective improvement. Larger scale studies would be needed in order to conclusively prove the effectiveness of BVT for patients with multiple sclerosis.

Delivery of melittin, the main component in bee venom, is also being studied by researchers at Washington University in St. Louis. By utilizing nanoparticles tipped with bee venom – so called “nanobees” – the researchers are seeking a cancer treatment with fewer side effects than conventional treatments. Nanobees work by delivering melittin, which destroys the cells around it by puncturing the cell membranes, directly to the cancer cells. However, unlike the melittin from bee stings, melittin attached to nanoparticles attacks only cells that have one particular protein on their surface, the protein that helps cancer cells to grow new blood vessels which is found only on tumor cells. After less than a week of treatment using nanobees, the growth of human breast cancer cells in mice had slowed by about 25 percent, and melanoma tumors in mice shrunk by 88 percent.

Monday, August 17, 2009

A Killer in the Developing World


HIV/AIDS and malaria are major health concerns worldwide, however the World Health Organization (WHO) reports across much of Asia and Africa secretory diarrhea - which accounts for 1.6 million deaths annually - is an even greater threat. Each day in India, diarrhea-related diseases kill 1,250 people, only slightly fewer than the H1N1 virus has killed globally to date (1,500), according to the WHO. Caused by E.coli, cholera, and other bacteria, viruses, or parasites, diarrhea affects individuals more often in areas that lack safe water and appropriate sanitation. In individuals with secretory diarrhea, infectious agents cause too much water to enter the bowel and be evacuated from the body, leading to excessive dehydration and eventually death if appropriate treatment is not received.


In nations of the developing world, including Bangladesh, India, Mali, and Pakistan, aid organizations and government agencies have begun distributing zinc supplements to villagers as a treatment for diarrhea. Data from recent studies documented in the August 2009 issue of the Journal of Leukocyte Biology suggest that zinc may help to activate the T-cells needed to destroy viruses and bacteria, including those that cause diarrhea. Time Magazine reports that in tablet or liquid form, zinc can be used in combination with oral-rehydration therapy (ORT). While it is not entirely clear how zinc helps halt diarrhea, Oliver Fontaine, a diarrhea specialist for the WHO, explains that a single course of zinc treatment can stave off diarrhea for three months.


Unlike zinc, which often produces an immediate improvement in an individual’s health, the glucose present in ORT (a solution of sugars and salts) slows the evacuation of fluids allowing for the absorption of electrolytes in the intestines, and halting the progression of dehydration to a chronic state. Because of the delay in the improvement of symptoms with ORT, “Mothers don’t see ORT as real treatment,” according to Eric Swedberg, senior director of health and nutrition at Save the Children U.S. Though ORT is an effective treatment for diarrhea, only about 35 percent of families in diarrhea-stricken countries utilize the method.


By offering zinc in combination with ORT, government-run programs in Ethiopia and Tanzania hope to increase the number of people surviving diarrheal outbreaks. Additionally, efforts are being made in Mali to add zinc to the country’s list of essential drugs, a step towards improving the distribution of the tablets. To halt the recent outbreaks of diarrhea in Nepal that have led to 235 deaths to date, the Office of the Prime Minister has begun coordinating efforts to construct a toilet in each household, provide sources of potable water, and improve waste disposal systems. In addition, the Nepali government has mobilized 298 personnel to aid in providing treatment in the area through 89 health camps.


To support these and other similar efforts, funding for the provision of the potentially life-saving drugs, and awareness of their effectiveness must be increased. In 2007, only four percent of all U.S. funding for research of epidemics in the developing world was devoted to finding solutions to decreasing the number of diarrhea-related deaths. Support from organizations like the Bill and Melinda Gates Foundation have provided some support, but additional funding is still needed not only to ensure that zinc tablets are more widely distributed, but also to assist in efforts to improve the quality of available water and waste treatment measures.


Discuss This and Other Public Health Concerns in the iCons in Medicine Forums


WHO on Water Treatment and Safe Storage - On Diarrhea and Tuberculosis in India - Time Magazine on Zinc to Treat Diarrhea - Diarrheal Deaths in Nepal - On Zinc Fighting Infection

Monday, August 3, 2009

Innovative, Low-Cost Medical and Diagnostic Tests


In the developing world, the availability of many medical technologies is limited by cost, durability, and ease-of-use. This is especially true of expensive diagnostic devices, which are critical for detecting diseases that are endemic in developing countries. However, researchers are working to develop low-cost, user-friendly alternatives that could improve the ability of healthcare providers to diagnose a range of conditions.


Harvard researchers have developed an alternative microfluidic device that replaces standard silicon, glass, or plastic substrates with treated paper. Fluids flow through the microchannels in the paper device in the same way that they would in a standard chip. Researchers have used the device to test for glucose and protein in urine, but hope to adapt it for the possibility of testing blood samples for HIV/AIDS, dengue fever, or hepatitis. While a traditional microfluidic device costs between $10 and $1,000USD, the materials to create the paper devices, known as microPADS, cost only three cents. The design of the microPAD device allows for several tests to be conducted simultaneously, furthering the cost and resource savings.


To help better diagnose infectious diseases such as malaria and tuberculosis, researchers have developed a microscope that attaches to any cellular telephone with a camera feature. The device, known as a CellScope, is able to illuminate pathogens in a sample treated with fluorescent molecular “tags.” It is estimated that the production of first CellScopes will cost roughly $1,000 each, but with further developments the price could drop to just a few hundred dollars, including the cell phone. Not only can an individual use the microscope to view the pathogens, but they can also send an image to a healthcare facility for assistance making an appropriate diagnostic determination.


Efforts have also been made by scientists at the Burnet Institute to improve HIV-testing procedures. A prototype monitoring test has been designed for use in remote settings. The new test, which uses a finger-prick blood sample, allows individuals to determine their CD4+ T-cell count within 30 minutes. The CD4+ T-cells are critical for healthy immune system function and their levels are a deciding factor with regard to starting anti-retroviral therapy. Standard CD4 tests are often not available in the developing world due to their cost, the need for specialized equipment and trained personnel, and the long wait period to obtain test results.


Though these diagnostic technologies offer improvements in the developing world, as The Wall Street Journal reports, acceptance may be slower in the United States. Some researchers have found success when applying African healthcare models to rural areas of the U.S., and results using low-cost technologies originally conceived for use in the developing world may follow this trend. The use of innovative low-cost testing methods may also assist with telemedicine initiatives, as they allow healthcare providers to conduct necessary tests and provide better diagnostic information to consultants. Through discussion among global health experts – as allowed by telemedicine initiatives like iCons in Medicine - innovative diagnostic tools and other cost-saving measures may become more popular, and help to provide improved care worldwide.


Contribute to the iCons in Medicine Forums and Discuss This Topic and Others


IEEE spectrum – Inside Technology - Discover Magazine on the microPAD and on the CellScope - Burnet Institute CD4+ T-cell Test